At Capsida, we’re passionate about developing innovative, best-in-class gene therapies for debilitating rare and common diseases across all ages. Our goal is to apply the strength of our targeted gene therapy platform to develop a new generation of transformative therapies.

We are inspired by the work we are doing with academic, clinical and industry leaders that share our vision and want to collaborate to help us reach more patients and benefit more lives. Since our inception, we have entered into strategic collaborations with AbbVie, CRISPR Therapeutics, Prevail Therapeutics, and Kate Therapeutics.

To discuss potential partnering opportunities, please contact us at

Collaborating with innovators who share our determination to develop transformative gene therapies for patients is an important component of our business strategy.

– Bethany Mancilla, Chief Business Officer


AbbVie Logo


In April 2021, Capsida announced a strategic collaboration and option agreement with AbbVie to create tissue-targeted gene therapies for three serious neurodegenerative diseases. In February 2023, we expanded our strategic collaboration with AbbVie to develop targeted genetic medicines for eye diseases with high unmet need.

Read more about our original CNS collaboration with AbbVie.
Read more about our expanded ophthalmology collaboration with AbbVie.

Prevail Therapeutics©

In January 2023, Capsida announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, to develop transformative, non-invasive gene therapies for CNS diseases.

Read more about our collaboration with Prevail Therapeutics.

Crispr logo

CRISPR Therapeutics©

In June 2021, Capsida announced a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of Friedreich’s ataxia.

Kate Therapeutics

Kate Therapeutics©

In October 2023, Capsida announced a strategic partnership that leverages Capsida’s next-generation manufacturing capabilities to enable development of Kate Therapeutics’ gene therapy medicines for muscle and heart diseases. Under the terms of the agreement, Capsida will provide GMP manufacturing of Kate Therapeutics’ gene therapies as the medicines advance through preclinical and clinical development.


Capsida is proud to partner with these industry associations to advance biotechnology solutions for patients, support regenerative therapies like gene therapy, and promote gender equality.